CONCORDBIO — Concord Biotech Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapHigh Flyer

Annual income statement for Concord Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	6,169	7,129	8,532	10,169	12,001
Cost of Revenue
Gross Profit	4,655	4,773	5,753	6,828	8,946
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,147	4,893	5,621	6,389	7,481
Operating Profit	3,022	2,236	2,911	3,780	4,520
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,127	2,375	3,220	4,126	4,946
Provision for Income Taxes
Net Income After Taxes	2,349	1,749	2,401	3,081	3,716
Net Income Before Extraordinary Items
Net Income	2,349	1,749	2,401	3,081	3,716
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,349	1,749	2,401	3,081	3,716
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	22.5	16.7	23	29.4	35.5
Dividends per Share